Information Provided By:
Fly News Breaks for August 7, 2018
IONS
Aug 7, 2018 | 13:49 EDT
Piper Jaffray analyst Tyler Van Buren said he is keeping his "glass half full" Neutral rating on Ionis after the company reported Q2 results and provided updates on its clinical programs. Waylivra and Tegsedi represent "exciting" opportunities with $1B+ in peak global sales potential by 2025, but Van Buren said attention should be paid to the early launch metrics to gain additional confidence in their ultimate commercial success. The analyst has a $50 price target on Ionis shares.
News For IONS From the Last 2 Days
There are no results for your query IONS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.